MENDS2 was a large randomised trial comparing dexmedetomidine with propofol for sedation in mechanically ventilated adults with sepsis. The study tackled a clinically important question: could the choice of sedative influence outcomes beyond simply keeping the patient comfortable and synchronised with the ventilator? The trial found no significant difference in the primary outcome of ventilator-free days and alive at 90 days between the two sedative strategies. The result is important because dexmedetomidine is often attractive when clinicians want lighter, more interactive sedation or less respiratory depression, but pharmacological preference should not be confused with proven mortality benefit. The practical message is to select sedation according to the patient's clinical needs, the desired depth of sedation, haemodynamic profile, delirium risk and the broader ICU liberation plan. Routine sedation should be as light as safely possible, with regular reassessment and coordination with spontaneous awakening and breathing trials. This fits CritiCARE 2026's dedicated discussion of sedation, analgesia, neuromuscular blockade, delirium and ventilator liberation. The trial reinforces a core principle of modern ICU practice: sedatives are tools within a care strategy, not endpoints in themselves.